Our mission
Our mission

Bring native bispecific therapeutics to patients

Our antibody development roots go deep

CD47 targeting
CD47 targeting

Safe and selective blockade of CD47 on tumors

Safe and selective blockade of CD47 on tumors

CD28 targeting

Safe and selective CD28 co-stimulation

Safe and selective blockade of CD47 on tumors

Who we are
Who we are

Our antibody development roots go deep

Our antibody development roots go deep

Our technology
Our technology, natural bispecific antibodies

Multispecific yet natural

κλ bodies

Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

previous arrow
next arrow
  • CD28 targeting
  • How it works
SITC 2021, NI-2601 & NI-2901 bispecific antibody programs

SITC 2021, NI-2601 & NI-2901 bispecific antibody programs


36th Annual Meeting & Pre-Conference Programs (SITC)

WASHINGTON, D.C/ SOCIETY FOR IMMUNOTHERAPY OF CANCER/ NOV.10-14, 2021 /

Light Chain Bioscience is very pleased to have Xavier Chauchet attend in-person the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 10-14, 2021 in Washington DC.

Xavier will present our innovative and differentiating CD47xPD-L1 bispecific antibodies for a simultaneous blockade of PD-1/PD-L1 and CD47/SIRPa immune checkpoint axes, NI-2601 and NI-2901. The programs are currently in late discovery phase and clinical lead candidates have been identified.

The poster entitled “CD47xPD-L1 bispecific antibodies for cancer therapy” (#265) will be exposed and presented on Nov. 12 between 9:55-10:10 a.m., 12:40-14:10 p.m., 4:35-4:50 p.m. and 7:00-8:30 p.m. and available on the SITC virtual meeting ePoster platform from 7 a.m. on Friday, Nov.12.

Read poster [PDF] :

sitc 2021 ni 2601 ni 2901 bispecific antibody programs 0


Walter E. Washington Convention Center

801 Mt Vernon Pl NW, Washington,
DC 20001, United States

+1 202-249-3000

First Patient dosed with NILK-2401 in Phase I clinical trial

First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body


Read more

LinkedIn